FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147996630> ?p ?o ?g. }

• W2147996630 endingPage "3133" @default.
• W2147996630 startingPage "3122" @default.
• W2147996630 abstract "Abstract In trial ALL-BFM 86, the largest multicenter trial of the Berlin- Frankfurt-Munster (BFM) study group for childhood acute lymphoblastic leukemia (ALL), treatment response was used as an overriding stratification factor for the first time. In the previous trial ALL-BFM 83, the in vivo response to initial prednisone treatment was evaluated prospectively. A blast cell count of > or = 1,000/microL peripheral blood after a 7-day exposure to prednisone and one intrathecal dose of methotrexate (MTX) identified 10% of the patients as having a significantly worse prognosis. In trial ALL-BFM 86 patients with > or = 1,000/microL blood blasts on day 8 were included in an experimental branch EG. Patients with < 1,000/microL blood blasts on day 8 were stratified by their leukemic cell burden into two branches, Standard Risk Group (SRG) and Risk Group (RG). SRG patients received an eight- drug induction followed by consolidation protocol M (6-mercaptopurine, high-dose [HD] MTX 4 x 5 g/m2) and maintenance. RG patients were treated with an additional eight-drug reinduction element. For EG patients protocol M was replaced by protocol E (prednisone, HD-MTX, HD- cytarabine, ifosfamide, mitoxantrone). All patients received intrathecal MTX therapy; only those of branches RG and EG received cranial irradiation. In branch RG, patients were randomized to receive or not to receive late intensification (prednisone, vindesine, teniposide, ifosfamide, HD-cytarabine) in the 13th month. During the trial reinduction therapy was introduced in branch SRG, because in the follow-up of trial ALL-BFM 83 the randomized low-risk patients receiving reinduction did significantly better. Nine hundred ninety- eight evaluable patients were enrolled, 28.6% in SRG, 61.1% in RG, 10.3% in EG. At a median follow-up of 5.0 (range 3.4 to 6.9) years, the estimated 6-year event-free survival was 72% +/- 2% for the study population, 58% +/- 5% in branch SRG for the first 110 patients without reinduction therapy, 87% +/- 3% for the next 175 patients with reinduction therapy, 75% +/- 2% in branch RG, and 48% +/- 5% in branch EG. Late intensification did not significantly affect treatment outcome of RG patients; however, only 23% of the eligible patients were randomized. Prednisone poor response remained a negative prognostic parameter despite intensified therapy. The results confirmed the benefit of intensive reinduction therapy even for low-risk patients. The strategy of induction, consolidation, and intensive reinduction may offer roughly 75% of unselected childhood ALL patients the chance for an event-free survival." @default.
• W2147996630 created "2016-06-24" @default.
• W2147996630 creator A5020812442 @default.
• W2147996630 creator A5033935778 @default.
• W2147996630 creator A5042645225 @default.
• W2147996630 creator A5051253426 @default.
• W2147996630 creator A5072090647 @default.
• W2147996630 creator A5073379037 @default.
• W2147996630 creator A5073421855 @default.
• W2147996630 creator A5082583670 @default.
• W2147996630 creator A5083099455 @default.
• W2147996630 creator A5090678844 @default.
• W2147996630 date "1994-11-01" @default.
• W2147996630 modified "2023-10-14" @default.
• W2147996630 title "Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86" @default.
• W2147996630 cites W120469029 @default.
• W2147996630 cites W128041213 @default.
• W2147996630 cites W141028238 @default.
• W2147996630 cites W1556688334 @default.
• W2147996630 cites W1580788756 @default.
• W2147996630 cites W1598597181 @default.
• W2147996630 cites W1939497674 @default.
• W2147996630 cites W1949967960 @default.
• W2147996630 cites W195883502 @default.
• W2147996630 cites W1968274099 @default.
• W2147996630 cites W1972795898 @default.
• W2147996630 cites W1979300931 @default.
• W2147996630 cites W19872180 @default.
• W2147996630 cites W2014375779 @default.
• W2147996630 cites W2018708925 @default.
• W2147996630 cites W2057268341 @default.
• W2147996630 cites W2058337944 @default.
• W2147996630 cites W2069194745 @default.
• W2147996630 cites W2072502760 @default.
• W2147996630 cites W2076426515 @default.
• W2147996630 cites W2096587673 @default.
• W2147996630 cites W2096830830 @default.
• W2147996630 cites W2128212240 @default.
• W2147996630 cites W2129762592 @default.
• W2147996630 cites W2138205116 @default.
• W2147996630 cites W2139984188 @default.
• W2147996630 cites W2144472683 @default.
• W2147996630 cites W2167990168 @default.
• W2147996630 cites W2278728288 @default.
• W2147996630 cites W2327443350 @default.
• W2147996630 cites W2474960249 @default.
• W2147996630 cites W2526018416 @default.
• W2147996630 cites W3214380612 @default.
• W2147996630 cites W328988336 @default.
• W2147996630 cites W55367026 @default.
• W2147996630 cites W8223099 @default.
• W2147996630 cites W2461854927 @default.
• W2147996630 doi "https://doi.org/10.1182/blood.v84.9.3122.3122" @default.
• W2147996630 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7949185" @default.
• W2147996630 hasPublicationYear "1994" @default.
• W2147996630 type Work @default.
• W2147996630 sameAs 2147996630 @default.
• W2147996630 citedByCount "588" @default.
• W2147996630 countsByYear W21479966302012 @default.
• W2147996630 countsByYear W21479966302013 @default.
• W2147996630 countsByYear W21479966302014 @default.
• W2147996630 countsByYear W21479966302015 @default.
• W2147996630 countsByYear W21479966302016 @default.
• W2147996630 countsByYear W21479966302017 @default.
• W2147996630 countsByYear W21479966302018 @default.
• W2147996630 countsByYear W21479966302019 @default.
• W2147996630 countsByYear W21479966302020 @default.
• W2147996630 countsByYear W21479966302021 @default.
• W2147996630 countsByYear W21479966302022 @default.
• W2147996630 countsByYear W21479966302023 @default.
• W2147996630 crossrefType "journal-article" @default.
• W2147996630 hasAuthorship W2147996630A5020812442 @default.
• W2147996630 hasAuthorship W2147996630A5033935778 @default.
• W2147996630 hasAuthorship W2147996630A5042645225 @default.
• W2147996630 hasAuthorship W2147996630A5051253426 @default.
• W2147996630 hasAuthorship W2147996630A5072090647 @default.
• W2147996630 hasAuthorship W2147996630A5073379037 @default.
• W2147996630 hasAuthorship W2147996630A5073421855 @default.
• W2147996630 hasAuthorship W2147996630A5082583670 @default.
• W2147996630 hasAuthorship W2147996630A5083099455 @default.
• W2147996630 hasAuthorship W2147996630A5090678844 @default.
• W2147996630 hasBestOaLocation W21479966301 @default.
• W2147996630 hasConcept C126322002 @default.
• W2147996630 hasConcept C141071460 @default.
• W2147996630 hasConcept C168563851 @default.
• W2147996630 hasConcept C204243189 @default.
• W2147996630 hasConcept C2776694085 @default.
• W2147996630 hasConcept C2776755627 @default.
• W2147996630 hasConcept C2778041864 @default.
• W2147996630 hasConcept C2778119113 @default.
• W2147996630 hasConcept C2778461978 @default.
• W2147996630 hasConcept C2778707968 @default.
• W2147996630 hasConcept C2778720950 @default.
• W2147996630 hasConcept C2779321808 @default.
• W2147996630 hasConcept C2779429289 @default.
• W2147996630 hasConcept C2780923524 @default.
• W2147996630 hasConcept C2781107101 @default.
• W2147996630 hasConcept C2909962599 @default.

• next